WARREN, N.J., June 09, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced the execution of a lease agreement to expand its corporate headquarters in Warren, New Jersey, more than doubling its footprint. The expanded space will centralize cross-functional teams, including executive leadership, regulatory affairs, corporate strategy, and research and development (previously located in Philadelphia), thereby increasing operational efficiency and enhancing ...

WARREN, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today provided stockholders with a detailed overview of its artificial intelligence initiative, Tevogen.AI™. Tevogen.AI™ aims to integrate advanced machine learning and predictive modeling into Tevogen Bio’s proprietary ExacTcell™ technology to significantly enhance its target identification and pre-clinical processes, thereby strengthening the Company’s pipeline of innovative immunotherapies, a ...

Core Insights - Tevogen Bio Holdings Inc. plans to expand the target population for its product TVGN 489 to include patients aged 65 and older, enhancing its market potential [1] - The top-line revenue forecast for the specialty care pipeline is projected at nearly $1 billion in its launch year, with a cumulative five-year estimate ranging between $18 billion and $22 billion [1] - The expansion aims to address significant unmet medical needs, particularly in light of the new COVID variant NB.1.8.1 [2] Company Developments - Tevogen's Chief Commercial Officer emphasized the importance of expanding clinical manufacturing capacity to meet the demands posed by the new COVID variant [2] - The expanded pipeline will include treatments for SARS-CoV-2 infection in various patient groups, including those with B cell hematologic cancer and patients aged 65 and older [5] Financial Projections - The updated forecast and risk-adjusted net present value (rNPV) will be provided to reflect the inclusion of the 65+ patient population [1] - The anticipated revenue growth reflects the company's strategic focus on specialty pharmaceuticals and addressing broader market needs [1]

WARREN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that it will provide several updates to stockholders in advance of the Company’s upcoming Annual Meeting of Stockholders scheduled for June 23, 2025. These updates will provide content regarding the Company’s innovative business model and strategic growth initiatives, which management believes position the Company strongly for future value realization. Ahead of the annual meeting ...

Financial Performance - Tevogen Bio reported a net loss of $10.4 million for the three months ended March 31, 2025, compared to a net loss of $11.3 million for the same period in 2024, primarily due to non-cash stock-based compensation expenses [136]. - The net loss for the three months ended March 31, 2025, was $10.4 million, compared to a net loss of $11.3 million for the same period in 2024 [156]. - Research and development expenses for the three months ended March 31, 2025, were $3.2 million, a decrease of 84.7% from $20.8 million for the same period in 2024 [157]. - General and administrative expenses for the three months ended March 31, 2025, were $7.2 million, down 17.7% from $8.7 million in the same period in 2024 [158]. - Cash used in operating activities for the three months ended March 31, 2025, was $3.3 million, compared to $2.2 million for the same period in 2024 [165][166]. Cash and Funding - As of March 31, 2025, Tevogen Bio had an accumulated deficit of $123.8 million and cash reserves of $2.0 million [136]. - As of March 31, 2025, the company had $2.0 million in cash, an increase from $1.3 million as of December 31, 2024 [163]. - The company raised aggregate gross proceeds of $24.0 million from the sale of convertible promissory notes since January 2021 [163]. - The company has drawn $3.0 million from a Loan Agreement with a remaining $27.0 million available for future financing [163]. - The company expects to utilize $8.0 million in grant funding from KRHP for ongoing operational expenses through March 31, 2026 [176]. - The company is exploring various funding strategies, including private placements and partnerships, to support operations [177]. Clinical Development - The first clinical product, TVGN 489, has completed a Phase 1 proof-of-concept trial with no dose-limiting toxicities observed, and secondary endpoints showed a rapid reduction in viral load [126]. - The company aims to commercialize TVGN 489 and other product candidates, expecting to incur expenses related to expanding research and development capabilities and building manufacturing infrastructure [141]. - The company plans to conduct clinical trials for TVGN 489 and other product candidates, which will require considerable financial resources [172]. - The company anticipates increased expenses related to commercialization if marketing approval for TVGN 489 is obtained [174]. Patent and Technology - Tevogen Bio's patent portfolio includes three issued U.S. patents related to TVGN 489, all expiring on December 9, 2040, and nine pending U.S. patent applications [130][131]. - Tevogen Bio's ExacTcell technology is designed to develop off-the-shelf T cell therapies with applications in infectious diseases and cancers [124]. Future Expectations - The company has not generated any revenue to date and does not expect to do so until marketing approval is obtained for its product candidates [141]. - The company expects general and administrative expenses to increase in the future to support ongoing research and development and potential commercialization efforts [149]. - The company expects to incur costs associated with operating as a public company, necessitating additional funding [174]. Obligations and Agreements - Total contractual obligations as of March 31, 2025, amount to $4,846,712, with $1,846,712 due within one year [179]. - The company has committed to a securities purchase agreement with the Patel Family for $6.0 million in Series C Preferred Stock [170]. - The company has not yet received $3.0 million of the $6.0 million purchase price for Series A-1 Preferred Stock [170]. - The company has entered into a Loan Agreement allowing for monthly draws of up to $1.0 million over 27 months, with a maximum loan amount of $36.0 million [171]. - The company has drawn an aggregate of $3.0 million under the Loan Agreement as of March 31, 2025, with an additional $0.5 million drawn in April 2025 [171].

WARREN, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that, following the Company’s recent press release highlighting the Direct Registration System (DRS) as a secure method of share ownership, it has received a number of inquiries from shareholders seeking additional information on how to transfer their shares to a DRS account. In response, Tevogen will provide step-by-step guidance early next week to help interested shareholders re ...

WARREN, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that CD8 Technology Services LLC (“CD8”) has signed a letter of intent for a facility designed to support Tevogen Bio’s cell therapy manufacturing facility. Tevogen Founder and CEO, Ryan Saadi, MD, MPH commented, “In-house manufacturing is critical to our operational efficiency, and with 74% insider ownership, we place the highest value on business discipline.” Forward Looking S ...

Core Viewpoint - Tevogen Bio Holdings Inc. informs shareholders about the differences between holding shares in Direct Registration System (DRS) accounts versus brokerage accounts, highlighting the benefits and drawbacks of each option [1]. Group 1: DRS Accounts - DRS accounts allow shares to be registered directly in the shareholder's name, providing direct control over the shares [2]. - Holding shares in DRS accounts may result in reduced transaction and account maintenance costs for shareholders [2]. Group 2: Brokerage Accounts - Brokerage accounts may offer greater access to investment tools and facilitate quicker selling of shares compared to DRS accounts [2]. - Investors may incur costs associated with transferring shares in and out of brokerage accounts [2]. Group 3: Additional Information - For further details regarding the differences between DRS and brokerage accounts, shareholders are encouraged to contact the Company's transfer agent, Continental Stock Transfer & Trust [3].

Reflects business philosophy of commercial success through patient accessibilityRecently executed agreement with CD 8 Technology Services LLC providing up to $50 million for Company’s dedicated R&D and manufacturing facility; no impact on shareholder equity WARREN, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), reaffirms its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5- ...

Core Viewpoint - Tevogen Bio Holdings Inc. will hold its 2025 annual meeting of stockholders via live webcast on June 23, 2025, where stockholders will vote on the re-election of two directors and the ratification of the independent accounting firm [1] Group 1 - Stockholders of record as of April 30, 2025, are encouraged to participate in the voting process, with proxy materials to be distributed in accordance with SEC regulations [2] - The Company plans to disclose the voting results on a Form 8-K after the Annual Meeting [3] - A proxy statement will be filed with the SEC, which stockholders are urged to read carefully as it will contain important information about the Company and the Annual Meeting [4] Group 2 - Stockholders can obtain free copies of the proxy statement and other SEC filings from the SEC's website or the Company's Investor Relations page [5] - The Company and its directors and executive officers may be considered participants in the proxy solicitation, with relevant information to be included in the proxy statement [6]